These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23494891)

  • 1. Regulation of selective PPARγ modulators in the differentiation of osteoclasts.
    Wu H; Li L; Ma Y; Chen Y; Zhao J; Lu Y; Shen P
    J Cell Biochem; 2013 Sep; 114(9):1969-77. PubMed ID: 23494891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.
    Fukunaga T; Zou W; Rohatgi N; Colca JR; Teitelbaum SL
    J Bone Miner Res; 2015 Mar; 30(3):481-8. PubMed ID: 25257948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
    Patel JJ; Butters OR; Arnett TR
    Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1.
    Yang CR; Lai CC
    Shock; 2010 Jun; 33(6):662-7. PubMed ID: 19953004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR agonists modulate human osteoclast formation and activity in vitro.
    Chan BY; Gartland A; Wilson PJ; Buckley KA; Dillon JP; Fraser WD; Gallagher JA
    Bone; 2007 Jan; 40(1):149-59. PubMed ID: 17010686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR gamma: ally and foe in bone metabolism.
    Wahli W
    Cell Metab; 2008 Mar; 7(3):188-90. PubMed ID: 18316021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.
    Lazarenko OP; Rzonca SO; Hogue WR; Swain FL; Suva LJ; Lecka-Czernik B
    Endocrinology; 2007 Jun; 148(6):2669-80. PubMed ID: 17332064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
    Kwak HB; Lee SW; Li YJ; Kim YA; Han SY; Jhon GJ; Kim HH; Lee ZH
    Biochem Pharmacol; 2004 Apr; 67(7):1239-48. PubMed ID: 15013839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss.
    Wei W; Wang X; Yang M; Smith LC; Dechow PC; Sonoda J; Evans RM; Wan Y
    Cell Metab; 2010 Jun; 11(6):503-16. PubMed ID: 20519122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
    Doshi LS; Brahma MK; Bahirat UA; Dixit AV; Nemmani KV
    Expert Opin Investig Drugs; 2010 Apr; 19(4):489-512. PubMed ID: 20367191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
    Idris AI; Landao-Bassonga E; Ralston SH
    Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
    Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
    FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
    Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
    Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
    Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.